Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
Preliminary HArmonyCa findings cover eight patients undergoing GLP-1 medical weight loss, with visible improvement at three months.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AbbVie (ABBV) will present eight scientific posters through Allergan Aesthetics at AMWC Dubai, taking place October 21–23, 2026. The research covers HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic, following HArmonyCa's recent UAE launch.
In a subgroup analysis, all eight participants using GLP-1 weight-loss medications and treated with HArmonyCa showed visible midface improvement at three months; the findings are preliminary. Other data include improved patient-reported neck appearance and satisfaction after SKINVIVE treatment and satisfaction with repeated BOTOX Cosmetic treatment among Middle Eastern patients.
Positive
- Minor pointHArmonyCa subgroup results showed visible midface improvement at three months in all eight participants using GLP-1 weight-loss medications.
- Minor pointSKINVIVE patient-reported outcomes showed improved neck appearance and satisfaction after treatment.
- Minor pointBOTOX Cosmetic research found most Middle Eastern patients satisfied with long-term repeated treatment for upper forehead lines.
Negative
- Minor pointHArmonyCa weight-loss findings remain preliminary, based on a subgroup of eight participants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM®, SKINVIVE™ and BOTOX® Cosmetic
- The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss
- The company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™
The program includes an expert-led symposium hosted by the Allergan Medical Institute (AMI), a global medical affairs symposium and multiple Meet the Expert sessions. Global and regional faculty will discuss the clinical evidence informing the AA Signature™ approach, which integrates treatments from across the Allergan Aesthetics portfolio into personalized treatment planning. The program will focus particularly on AA Signature™ Lift-Up and the introduction of HArmonyCa™ in the
Following its recent launch in the
"This meeting brings together the science, clinical expertise and education that continue to shape the aesthetics field in the
Growing evidence behind evolving Allergan Aesthetics portfolio
Data being presented at AMWC
As patients' aesthetic needs evolve over time, changes associated with medical weight loss can span facial volume, structure and skin quality, reinforcing the importance of personalized assessment and treatment planning that considers the patient more holistically. This research adds to the growing body of evidence investigating the use of the Allergan Aesthetics portfolio in patients navigating the effects of medical weight loss.
In a subgroup analysis of patients using glucagon-like peptide-1 (GLP-1) weight-loss medications, all eight participants treated with HArmonyCa™ showed visible midface improvement at three months, providing an early clinical signal for addressing facial volume changes in this emerging patient population. These findings offer preliminary evidence on the use of HArmonyCa™ in patients experiencing facial volume changes while undergoing GLP-1 medical weight loss.2
Additional clinical data being presented include patient-reported outcomes showing improvement in neck appearance and satisfaction after SKINVIVE™ treatment, alongside new original research examining patient-reported satisfaction, treatment benefits and motivations for retreatment among Middle Eastern patients receiving long-term, repeated BOTOX® Cosmetic treatment for upper facial lines. The majority of patients were satisfied with the effects of long-term repeated treatment upper forehead lines and reported feeling younger as a result of the treatment.4
On October 22, Allergan Aesthetics' global medical affairs team will bring together experts for the "Breakthrough Science in Aesthetics: New Frontiers in Clinical Outcomes and Care" symposium. Together, Dr. Mariola Galazka, Dr. Koenraad De Boulle and Dr. Mansi Mukherjee will discuss advances in neurotoxin science and innovation, long-term BOTOX® Cosmetic evidence and natural-looking outcomes of the portfolio, while highlighting the value of multimodal aesthetic approaches. They will also explore how emerging science can unlock new possibilities for key patient segments and shape the future of aesthetics.
Showcasing educational science
On October 21, AMI will host the "AA Signature™ Lift-Up Multimodal Approach with Regenerative Biostimulation" symposium. Dr. Raafat Lakis, Dr. Reha Yavuzer and Dr. Mariola Galazka will explore the AA Signature™ Lift-Up approach, HArmonyCa™ and DART® Technology as part of longer-term multimodal treatment planning. The program will also feature a live technique showcase and an expert panel discussion.
Practitioners can engage directly with faculty during Meet the Expert sessions at Allergan Aesthetics booth B16, covering the AA Signature™ Lift-Up approach, clinical considerations in facial neurotoxin treatment and the importance of building trust through clinical expertise.
Collectively, the program underscores Allergan Aesthetics' commitment to advancing personalized, evidence-led aesthetics.
|
Type |
Title |
Authors |
|
BOTOX® Cosmetic |
||
|
Original |
Patient-Perceived Satisfaction and Benefits of |
Mukherjee M, Aleisa |
|
HArmonyCa™ |
||
|
Encore |
Complete Analysis of a 24-Month Multicenter, |
Humphrey S, |
|
Encore |
Treatment of Midface Volume Deficits with a |
Humphrey S, Nikolis |
|
Encore |
An Evaluation of the Mechanism of Action of a |
Braz A, Chang N, |
|
JUVÉDERM®/HA fillers |
||
|
Encore |
Patient Reported Satisfaction and Improvement |
Cox SE, Palm M, |
|
Encore |
Cross-linked Hyaluronic Acid Gel's Secondary |
Kutikov A, Pierce A, |
|
Encore |
Assessing the Potential for Injectable HA Gel |
Pierce A, Ly J, Nakab |
|
Encore |
Evaluation of Degradation Kinetics and |
Kutikov A, Nakab L |
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
- Braz A, Eduardo CC de P, Pierce A, et al. A Novel Hybrid Injectable for Soft-tissue Augmentation: Analysis of Data and Practical Experience. Plast Reconstr Surg Glob Open. 2024;12(9):e6190.
- Humphrey S, Nikolis A, Urdiales Gálvez F, et al. Treatment of Midface Volume Deficits with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Injectable in Participants Undergoing GLP-1 Medical Weight Loss: A Safety and Efficacy Subgroup Analysis from a Pivotal Study. To be presented at AMWC Dubai 2026; Dubai, UAE.
- Humphrey S, Demosthenous N, Nikolis A, et al. Complete Analysis of a 24-Month Multicenter, Evaluator-Blinded, Randomized, Parallel-Group Study to Evaluate the Safety and Effectiveness of a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Injectable for Midface Soft Tissue Augmentation. To be presented at AMWC Dubai 2026; Dubai, UAE.
- Mukherjee M, Aleisa AM, Raza A, Musumeci M. Patient-Perceived Satisfaction and Benefits of Long-Term OnabotulinumtoxinA for Upper Facial Lines: A Sub-Analysis of Patients From Middle Eastern Sites From a Global Retrospective Chart Review and Cross-Sectional Study. To be presented at AMWC Dubai 2026; Dubai, UAE.
|
U.S. Media: Adelle Infante +1 (847) 224-0359 adelle.infante@allergan.com
Michael Salzillo +1 (908) 269-1688 michael.salzillo@abbvie.com |
Investors: Liz Shea +1 (847) 935-2211 liz.shea@abbvie.com |
View original content:https://www.prnewswire.com/news-releases/allergan-aesthetics-deepens-science-behind-multimodal-approach-at-amwc-dubai-backed-by-growing-harmonyca-evidence-302914823.html
SOURCE AbbVie
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AbbVie's HArmonyCa research show in patients using GLP-1 weight-loss medications?
All eight participants using GLP-1 weight-loss medications and treated with HArmonyCa showed visible midface improvement at three months. The subgroup analysis provides preliminary evidence in patients experiencing facial volume changes during medical weight loss.
Does AbbVie's AMWC Dubai program include longer-term HArmonyCa research?
The program includes a complete analysis of a 24-month study evaluating HArmonyCa's safety and effectiveness for midface soft tissue augmentation. The study was multicenter, evaluator-blinded and randomized, with parallel treatment groups.